Easton Pharmaceuticals, Inc designs, produces, and sells premium health care products. Most of them use the proprietary transdermal gel formulation that the Canadian company has developed. In 2013, Easton Pharma also announced that it has begun breaking into the medical marijuana sector.
The company was founded in 1997 and originally operated as LAM Pharmaceutical Corp. It became Easton Pharmaceuticals, Inc in 2010.
With a market cap pegged at USD 1.26 M, Easton Pharmaceuticals currently trades in the OTC markets as EAPH.
Products of the company are targeted towards various health issues. Most are applied topically but have transdermal effects due to Easton’s unique proprietary delivery system. There is the arthritis- and body-pain reliever Kenestrin Gel, the anti-wrinkle cream Skin Renou HA, the female sexual enhancement gel Viorra, and the motion sickness reliever gel Nauseasol.
In addition, Easton Pharmaceuticals is working on two major products in its pipeline. These are the early-stage cancer drug called XILIVE and the transdermal treatment for Female Sexual Arousal Disorder (FSAD) called Femlife.
For its entry into the marijuana industry, Easton Pharmaceuticals revealed its intention to establish medical marijuana clinics in Canada and the US. It has also started to discuss investment proposals, such as the one with a Michigan-based medical marijuana dispensary.
The company’s biggest move so far on this front is its investment in AMFIL Technologies. AMFIL is the manufacturer of a plant-growing system called the mPact-GROzone Antimicrobial System, whose technologies reduce pathogens and pests inside cannabis grow facilities.
Easton Pharmaceuticals, Inc is led by CEO and President Carla Pepe, CFO John Adams, COO Kent A Deuters, Treasurer Dr. Peter J. Rothbart, and Chief Marketing and Technology Officer Dr. Lilla Albert. Alongside them is Dr. Daniel Bagi as the Senior Executive Physician Consultant.
Yahoo! Finance: EAPH News
Latest Financial News for EAPH
TORONTO, June 13, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Easton Pharmaceuticals Inc. (OTC: EAPH) (“Easton” or “the Company”) announces it has filed its quarterly report for the three months ended March 31, 2019, and provides several key updates on its business initiatives. In the first quarter of 2019, Easton Pharmaceuticals recorded revenues of $612,689 and turned from a loss to post net income of $7,878. Revenues were generated from the Company’s contract with a prominent developer to frame 150 new homes in Whitby, Ontario, Canada, under its newly created real estate development division.
TORONTO, ON / ACCESSWIRE / April 30, 2019 / Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) executive management is pleased to announce the move of its corporate head office from Elm Street, Toronto, Ontario to Brockhouse Road, Toronto, Ontario. Easton confirms that with the acquisition of Supreme Sweets Inc. the management will be joining the Easton team at the Brockhouse Road facility and adding the extensive product line up to its growing product group within the Company's Food and Beverage operation. This move will allow Easton to oversee their Food & Beverage, Real Estate and Gaming all within the same physical premises.
TORONTO, ON / ACCESSWIRE / April 24, 2019 / Easton Pharmaceuticals, Inc. (the "Company" or "Easton") (OTC PINK: EAPH) is pleased to announce that it has now officially closed on its acquisition of a food processing company based in Toronto, Canada. Easton has completed its acquisition of Supreme Sweets Inc. and 2498411 Ontario Inc. (collectively the "Acquiree"), which includes all the tangible and intangible assets of the company such as equipment, intellectual property (patents, trade secrets, formulas, etc.) and client lists of both Supreme Sweets Inc. and 2498411 Ontario Inc. The purchase was completed with a combination of cash and Easton stock.
TORONTO, ON / ACCESSWIRE / April 12, 2019 / Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) provides update on the closing of its agreement to acquire a commercial bakery with existing revenues and projected to reach over $20,000,000 within 12 months. Easton announced earlier this week that its legal counsel believed that all documents would be completed this week with signatures and exchange of documents. Easton is acquiring a revenue generating commercial bakery and food preparation company in Toronto, Ontario, Canada.
TORONTO, ON / ACCESSWIRE / April 8, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) provides update on the closing of its agreement to acquire a commercial bakery with existing revenues and projected to reach over $20,000,000 within 12 months. Easton announced earlier in March that it had signed a Definitive Agreement to acquire a commercial bakery and food preparation company with existing revenues and projected revenues in excess of $20,000,000 over the next 12 months. Easton's legal counsel believes that all documents will be completed this week with signatures and exchange of documents.
